Skip to main content

Advertisement

SpringerLink
Log in

Preclinical evaluation of sunitinib as single agent or in combination with chemotherapy in nasopharyngeal carcinoma

  • PRECLINICAL STUDIES
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

Purpose: Sunitinib is a multi-target receptor tyrosine kinase (RTK) inhibitor against vascular endothelial growth factor receptors, platelet-derived growth factor receptors (PDGFR), c-kit and RET. Several of these RTKs are known to be involved in the progression of nasopharyngeal carcinoma (NPC). Here, we evaluated the preclinical activities of sunitinib in NPC. Method: We determined the basal level of total and phosphorylated PDGFR, c-kit and RET by immunoblotting in a panel of five NPC cell lines. The effect of sunitinib on NPC cell proliferation was evaluated by MTT assay. We further studied the effect of sunitinib on NPC cell cycle progression and apoptosis. We investigated the in vitro and in vivo activities of sunitinib as single agent and in combination with cisplatin or docetaxel in NPC cell lines and tumor xenografts. Results: Sunitinib exhibited dose-dependent growth inhibition in all NPC cell lines tested with IC50 between 2–7.5 μM and maximum inhibition of over 97%. Sunitinib induced apoptosis and cell cycle arrest at G0/G1 phase. In vitro, sunitinib moderately enhanced the growth inhibition of cisplatin or docetaxel. Single agent sunitinib demonstrated significant growth inhibition, reduced microvessel density and caused extensive tumor necrosis in a NPC xenograft model. However, concurrent administration of sunitinib and docetaxel induced severe toxicity in mice without enhanced antitumor effect. Conclusions: Single agent sunitinib demonstrated potent in vitro and in vivo growth inhibition in NPC. When combined with chemotherapy, sequential instead of concurrent administration schedule should be further explored.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Chan AT, Teo PM, Huang DP (2004) Pathogenesis and treatment of nasopharyngeal carcinoma. Semin Oncol 31:794–801

    Article  PubMed  Google Scholar 

  2. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74–108

    Article  PubMed  Google Scholar 

  3. Hong Kong Cancer Stat (2007) Hong Kong Cancer Registry, Hospital Authority. Available from http://www3.ha.org.hk/cancereg/

  4. Ma BB, Hui EP, Chan AT (2008) Systemic approach to improving treatment outcome in nasopharyngeal carcinoma: current and future directions. Cancer Sci 99:1311–1318

    Article  PubMed  CAS  Google Scholar 

  5. Hui EP, Leung SF, Au JS, Zee B, Tung S, Chua D, Sze WM, Law CK, Leung TW, Chan AT (2004) Lung metastasis alone in nasopharyngeal carcinoma: a relatively favorable prognostic group. A study by the Hong Kong Nasopharyngeal Carcinoma Study Group. Cancer 101:300–306

    Article  PubMed  Google Scholar 

  6. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, Murray LJ, Carver J, Chan E, Moss KG, Haznedar JO, Sukbuntherng J, Blake RA, Sun L, Tang C, Miller T, Shirazian S, McMahon G, Cherrington JM (2003) In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9:327–337

    PubMed  CAS  Google Scholar 

  7. Potapova O, Laird AD, Nannini MA, Barone A, Li G, Moss KG, Cherrington JM, Mendel DB (2006) Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248. Mol Cancer Ther 5:1280–1289

    Article  PubMed  CAS  Google Scholar 

  8. Christensen JG (2007) A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumour activities. Ann Oncol 18(Suppl 10):x3–x10

    Article  PubMed  Google Scholar 

  9. Faivre S, Demetri G, Sargent W, Raymond E (2007) Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov 6:734–745

    Article  PubMed  CAS  Google Scholar 

  10. Chow LQ, Eckhardt SG (2007) Sunitinib: from rational design to clinical efficacy. J Clin Oncol 25:884–896

    Article  PubMed  CAS  Google Scholar 

  11. Sha D, He YJ (2006) Expression and clinical significance of VEGF and its receptors Flt-1 and KDR in nasopharyngeal carcinoma. Ai Zheng 25:229–234

    PubMed  CAS  Google Scholar 

  12. Xiao X, Wu J, Zhu X, Zhao P, Zhou J, Liu QQ, Zheng L, Zeng M, Liu R, Huang W (2007) Induction of cell cycle arrest and apoptosis in human nasopharyngeal carcinoma cells by ZD6474, an inhibitor of VEGFR tyrosine kinase with additional activity against EGFR tyrosine kinase. Int J Cancer 121:2095–2104

    Article  PubMed  CAS  Google Scholar 

  13. Qian CN, Min HQ, Lin HL, Hong MH, Ye YL (1998) Primary study in experimental antiangiogenic therapy of nasopharyngeal carcinoma with AGM-1470 (TNP-470). J Laryngol Otol 112:849–853

    Article  PubMed  CAS  Google Scholar 

  14. Qian CN, Min HQ, Lin HL, Feng GK, Ye YL, Wang LG, Kuang ZJ (1999) Anti-tumor effect of angiogenesis inhibitor TNP-470 on the human nasopharyngeal carcinoma cell line NPC/HK1. Oncology 57:36–41

    Article  PubMed  CAS  Google Scholar 

  15. Wakisaka N, Wen QH, Yoshizaki T, Nishimura T, Furukawa M, Kawahara E, Nakanishi I (1999) Association of vascular endothelial growth factor expression with angiogenesis and lymph node metastasis in nasopharyngeal carcinoma. Laryngoscope 109:810–814

    Article  PubMed  CAS  Google Scholar 

  16. Guang-Wu H, Sunagawa M, Jie-En L, Shimada S, Gang Z, Tokeshi Y, Kosugi T (2000) The relationship between microvessel density, the expression of vascular endothelial growth factor (VEGF), and the extension of nasopharyngeal carcinoma. Laryngoscope 110:2066–2069

    Article  PubMed  CAS  Google Scholar 

  17. Qian CN, Zhang CQ, Guo X, Hong MH, Cao SM, Mai WY, Min HQ, Zeng YX (2000) Elevation of serum vascular endothelial growth factor in male patients with metastatic nasopharyngeal carcinoma. Cancer 88:255–261

    Article  PubMed  CAS  Google Scholar 

  18. Sung FL, Hui EP, Tao Q, Li H, Tsui NB, Dennis Lo YM, Ma BB, To KF, Harris AL, Chan AT (2007) Genome-wide expression analysis using microarray identified complex signaling pathways modulated by hypoxia in nasopharyngeal carcinoma. Cancer Lett 253:74–88

    Article  PubMed  CAS  Google Scholar 

  19. Hui EP, Chan AT, Pezzella F, Turley H, To KF, Poon TC, Zee B, Mo F, Teo PM, Huang DP, Gatter KC, Johnson PJ, Harris AL (2002) Coexpression of hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival. Clin Cancer Res 8:2595–2604

    PubMed  CAS  Google Scholar 

  20. Murono S, Inoue H, Tanabe T, Joab I, Yoshizaki T, Furukawa M, Pagano JS (2001) Induction of cyclooxygenase-2 by Epstein-Barr virus latent membrane protein 1 is involved in vascular endothelial growth factor production in nasopharyngeal carcinoma cells. Proc Natl Acad Sci U S A 98:6905–6910

    Article  PubMed  CAS  Google Scholar 

  21. Ma BB, Poon TC, To KF, Zee B, Mo FK, Chan CM, Ho S, Teo PM, Johnson PJ, Chan AT (2003) Prognostic significance of tumor angiogenesis, Ki 67, p53 oncoprotein, epidermal growth factor receptor and HER2 receptor protein expression in undifferentiated nasopharyngeal carcinoma–a prospective study. Head Neck 25:864–872

    Article  PubMed  Google Scholar 

  22. Foote RL, Weidner N, Harris J, Hammond E, Lewis JE, Vuong T, Ang KK, Fu KK (2005) Evaluation of tumor angiogenesis measured with microvessel density (MVD) as a prognostic indicator in nasopharyngeal carcinoma: results of RTOG 9505. Int J Radiat Oncol Biol Phys 61:745–753

    Article  PubMed  Google Scholar 

  23. Krishna SM, James S, Balaram P (2006) Expression of VEGF as prognosticator in primary nasopharyngeal cancer and its relation to EBV status. Virus Res 115:85–90

    Article  PubMed  CAS  Google Scholar 

  24. Bar-Sela G, Kuten A, Ben-Eliezer S, Gov-Ari E, Ben-Izhak O (2003) Expression of HER2 and C-KIT in nasopharyngeal carcinoma: implications for a new therapeutic approach. Mod Pathol 16:1035–1040

    Article  PubMed  CAS  Google Scholar 

  25. Sheu LF, Lee WC, Lee HS, Kao WY, Chen A (2005) Co-expression of c-kit and stem cell factor in primary and metastatic nasopharyngeal carcinomas and nasopharyngeal epithelium. J Pathol 207:216–223

    Article  PubMed  CAS  Google Scholar 

  26. Sheu LF, Young ZH, Lee WC, Chen YF, Kao WY, Chen A (2007) STI571 sensitizes nasopharyngeal carcinoma cells to cisplatin: sustained activation of ERK with improved growth inhibition. Int J Oncol 30:403–411

    PubMed  CAS  Google Scholar 

  27. Mocanu JD, Yip KW, Alajez NM, Shi W, Li JH, Lunt SJ, Moriyama EH, Wilson BC, Milosevic M, Lo KW, van Rooijen N, Busson P, Bastianutto C, Liu FF (2007) Imaging the modulation of adenoviral kinetics and biodistribution for cancer gene therapy. Mol Ther 15:921–929

    PubMed  CAS  Google Scholar 

  28. Sizhong Z, Xiukung G, Yi Z (1983) Cytogenetic studies on an epithelial cell line derived from poorly differentiated nasopharyngeal carcinoma. Int J Cancer 31:587–590

    Article  PubMed  CAS  Google Scholar 

  29. Glaser R, Zhang HY, Yao KT, Zhu HC, Wang FX, Li GY, Wen DS, Li YP (1989) Two epithelial tumor cell lines (HNE-1 and HONE-1) latently infected with Epstein-Barr virus that were derived from nasopharyngeal carcinomas. Proc Natl Acad Sci U S A 86:9524–9528

    Article  PubMed  CAS  Google Scholar 

  30. Cheung ST, Huang DP, Hui AB, Lo KW, Ko CW, Tsang YS, Wong N, Whitney BM, Lee JC (1999) Nasopharyngeal carcinoma cell line (C666-1) consistently harbouring Epstein-Barr virus. Int J Cancer 83:121–126

    Article  PubMed  CAS  Google Scholar 

  31. Huang DP, Ho JH, Poon YF, Chew EC, Saw D, Lui M, Li CL, Mak LS, Lai SH, Lau WH (1980) Establishment of a cell line (NPC/HK1) from a differentiated squamous carcinoma of the nasopharynx. Int J Cancer 26:127–132

    Article  PubMed  CAS  Google Scholar 

  32. Sung FL, Poon TC, Hui EP, Ma BB, Liong E, To KF, Huang DP, Chan AT (2005) Antitumor effect and enhancement of cytotoxic drug activity by cetuximab in nasopharyngeal carcinoma cells. In Vivo 19:237–245

    PubMed  CAS  Google Scholar 

  33. Lui VW, Boehm AL, Koppikar P, Leeman RJ, Johnson D, Ogagan M, Childs E, Freilino M, Grandis JR (2007) Antiproliferative mechanisms of a transcription factor decoy targeting signal transducer and activator of transcription (STAT) 3: the role of STAT1. Mol Pharmacol 71:1435–1443

    Article  PubMed  CAS  Google Scholar 

  34. Wong JH, Lui VW, Umezawa K, Ho Y, Wong EY, Ng MH, Cheng SH, Tsang CM, Tsao SW, Chan AT (2010) A small molecule inhibitor of NF-kappaB, dehydroxymethylepoxyquinomicin (DHMEQ), suppresses growth and invasion of nasopharyngeal carcinoma (NPC) cells. Cancer Lett 287:23–32

    Article  PubMed  CAS  Google Scholar 

  35. Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM (2003) SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2:471–478

    PubMed  CAS  Google Scholar 

  36. Ikezoe T, Nishioka C, Tasaka T, Yang Y, Komatsu N, Togitani K, Koeffler HP, Taguchi H (2006) The antitumor effects of sunitinib (formerly SU11248) against a variety of human hematologic malignancies: enhancement of growth inhibition via inhibition of mammalian target of rapamycin signaling. Mol Cancer Ther 5:2522–2530

    Article  PubMed  CAS  Google Scholar 

  37. O’Farrell AM, Abrams TJ, Yuen HA, Ngai TJ, Louie SG, Yee KW, Wong LM, Hong W, Lee LB, Town A, Smolich BD, Manning WC, Murray LJ, Heinrich MC, Cherrington JM (2003) SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 101:3597–3605

    Article  PubMed  Google Scholar 

  38. Maris JM, Courtright J, Houghton PJ, Morton CL, Kolb EA, Lock R, Tajbakhsh M, Reynolds CP, Keir ST, Wu J, Smith MA (2008) Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program. Pediatr Blood Cancer 51:42–48

    Article  PubMed  Google Scholar 

  39. Abrams TJ, Murray LJ, Pesenti E, Holway VW, Colombo T, Lee LB, Cherrington JM, Pryer NK (2003) Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with “standard of care” therapeutic agents for the treatment of breast cancer. Mol Cancer Ther 2:1011–1021

    PubMed  CAS  Google Scholar 

  40. Murray LJ, Abrams TJ, Long KR, Ngai TJ, Olson LM, Hong W, Keast PK, Brassard JA, O’Farrell AM, Cherrington JM, Pryer NK (2003) SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis 20:757–766

    Article  PubMed  CAS  Google Scholar 

  41. Cumashi A, Tinari N, Rossi C, Lattanzio R, Natoli C, Piantelli M, Iacobelli S (2008) Sunitinib malate (SU-11248) alone or in combination with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts. Cancer Lett 270:229–233

    Article  PubMed  CAS  Google Scholar 

  42. Guerin O, Formento P, Lo Nigro C, Hofman P, Fischel JL, Etienne-Grimaldi MC, Merlano M, Ferrero JM, Milano G (2008) Supra-additive antitumor effect of sunitinib malate (SU11248, Sutent) combined with docetaxel. A new therapeutic perspective in hormone refractory prostate cancer. J Cancer Res Clin Oncol 134:51–57

    Article  PubMed  CAS  Google Scholar 

  43. Sonpavde G, Jian W, Liu H, Wu MF, Shen SS, Lerner SP (2009) Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model. Urol Oncol 27:391–399

    Article  PubMed  CAS  Google Scholar 

  44. Czabanka M, Vinci M, Heppner F, Ullrich A, Vajkoczy P (2009) Effects of sunitinib on tumor hemodynamics and delivery of chemotherapy. Int J Cancer 124:1293–1300

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgement

Supported by research fund from Li Ka Shing Institute of Health Sciences to Cancer Drug Testing Unit, Department of Clinical Oncology, The Chinese University of Hong Kong.

Author information

Authors and Affiliations

  1. Cancer Drug Testing Unit, Department of Clinical Oncology, State Key Laboratory in Oncology in South China, The Chinese University of Hong Kong, Shatin, Hong Kong

    Edwin Pun Hui, Vivian W. Y. Lui, Cesar S. C. Wong, Brigette B. Y. Ma, Cecilia P. Y. Lau, Crystal S. F. Cheung, Kakiu Ho & Anthony T. C. Chan

  2. Sir YK Pao Center for Cancer, Hong Kong Cancer Institute, The Chinese University of Hong Kong, Shatin, Hong Kong

    Edwin Pun Hui, Vivian W. Y. Lui, Cesar S. C. Wong, Brigette B. Y. Ma, Cecilia P. Y. Lau, Crystal S. F. Cheung, Kakiu Ho & Anthony T. C. Chan

  3. Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Shatin, Hong Kong

    Edwin Pun Hui, Vivian W. Y. Lui, Cesar S. C. Wong, Brigette B. Y. Ma, Cecilia P. Y. Lau, Crystal S. F. Cheung, Kakiu Ho & Anthony T. C. Chan

  4. Department of Anatomical and Cellular Pathology, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong

    Suk-hang Cheng & Margaret H. L. Ng

  5. Department of Clinical Oncology, The Chinese University of Hong Kong, Prince of Wales Hospital, 30-32 Ngan Shing Street, Shatin, Hong Kong

    Anthony T. C. Chan

Authors
  1. Edwin Pun Hui
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Vivian W. Y. Lui
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Cesar S. C. Wong
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Brigette B. Y. Ma
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Cecilia P. Y. Lau
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Crystal S. F. Cheung
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Kakiu Ho
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Suk-hang Cheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Margaret H. L. Ng
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Anthony T. C. Chan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anthony T. C. Chan.

Additional information

Edwin P. Hui and Vivian W. Y. Lui co-first authors.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hui, E.P., Lui, V.W.Y., Wong, C.S.C. et al. Preclinical evaluation of sunitinib as single agent or in combination with chemotherapy in nasopharyngeal carcinoma. Invest New Drugs 29, 1123–1131 (2011). https://doi.org/10.1007/s10637-010-9451-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10637-010-9451-1

Keyword

Search

Navigation